REGN
Regeneron Pharmaceuticals, Inc.
Income statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.9B | 14.3B | 14.2B | 13.1B | 12.2B | 16.1B | 8.5B | 6.6B | 5.1B | 5.9B | 4.9B | 4.1B | 2.8B | 2.1B | 1.4B | 446M | 459M | 379M | 238M |
Cost of revenue | — | — | — | — | — | — | — | 403M | 238M | 203M | 195M | 242M | 129M | 118M | 84M | 4.2M | 2.1M | 1.7M | 923K |
| Gross profit | — | — | — | — | — | — | — | 6.15B | 4.91B | 5.67B | 4.67B | 3.86B | 2.69B | 1.99B | 1.29B | 0.44B | 0.46B | 0.38B | 0.24B |
| 6.60B | 5.85B | 5.13B | 4.44B | 3.59B | 2.86B | 2.65B | 2.45B | 1.47B | 2.08B | 2.05B | 1.62B | 1.27B | 0.86B | 0.63B | 0.53B | 0.49B | 0.40B | 0.27B | |
| 2.76B | 2.70B | 2.95B | 2.63B | 2.12B | 1.82B | 1.35B | 1.34B | 1.13B | 1.32B | 1.18B | 0.84B | 0.52B | 0.35B | 0.21B | 0.12B | 65M | 53M | 49M | |
Other operating expenses | — | — | — | — | — | — | — | 153M | — | 195M | 105M | 151M | 76M | 37M | — | — | — | — | — |
| Operating income | 4.86B | 3.58B | 3.99B | 4.05B | 4.74B | 8.95B | 3.58B | 2.21B | 2.53B | 2.08B | 1.33B | 1.25B | 0.82B | 0.74B | 0.46B | −0.21B | −97M | −74M | −86M |
Non-operating income | 0.82B | 1.65B | 0.79B | 0.15B | 0.12B | 0.38B | 0.23B | 0.22B | 19M | −1.1M | −900K | −27M | −63M | −47M | −43M | −18M | −7.0M | 2.2M | 9.5M |
| Pretax income | 5.69B | 5.23B | 4.78B | 4.20B | 4.86B | 9.33B | 3.81B | 2.43B | 2.55B | 2.08B | 1.33B | 1.23B | 0.76B | 0.70B | 0.41B | −0.22B | −0.10B | −72M | −77M |
Taxes | 0.87B | 0.73B | 0.37B | 0.25B | 0.52B | 1.25B | 0.30B | 0.31B | 0.11B | 0.88B | 0.43B | 0.59B | 0.42B | 0.28B | −0.34B | −1.1M | 0 | −4.1M | 2.4M |
| Net income | 4.82B | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B | 2.12B | 2.44B | 1.20B | 0.90B | 0.64B | 0.34B | 0.41B | 0.75B | −0.22B | −0.10B | −68M | −79M |
| Diluted EPS | 45.29 | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 | 3.72 | 6.75 | −2.45 | −1.26 | −0.85 | — |
| Diluted shares | — | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M | 115.2M | 113.4M | 111.3M | 115.4M | 90.6M | 82.9M | — | — |
| Revenue growth | — | +1.0% | +8.3% | +7.8% | −24.3% | +89.1% | +29.6% | +27.4% | −12.4% | +20.8% | +18.4% | +45.5% | +34.0% | +52.7% | +209.2% | −2.9% | +21.0% | +59.1% | — |
| Gross margin | — | — | — | — | — | — | — | 93.9% | 95.4% | 96.6% | 96.0% | 94.1% | 95.4% | 94.4% | 93.9% | 99.1% | 99.5% | 99.6% | 99.6% |
| Operating margin | 28.8% | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 33.7% | 49.3% | 35.4% | 27.4% | 30.5% | 29.2% | 35.3% | 33.2% | −46.0% | −21.2% | −19.5% | −36.2% |
| Net margin | 28.5% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% | 15.5% | 12.0% | 19.7% | 54.4% | −49.7% | −22.8% | −17.9% | −33.2% |